Customer Letters

Please note: The following Customer Letters, do not replace the version that you receive from your local Canadian Blood Services site.

* The contents of the customer letters available on this site are current as of their dates of publication. If required, contact your local Hospital Liaison Specialist to determine if the letter is still current.

Displaying 1 - 12 of 12

	Date Sort ascending
CL_2022-12.pdf	2022-04-11	INFORMATION ONLY Adynovate^® Ancillary Item Changes Customer Letter 2022-12 (PDF) \| ADYNOVATE^® changes and timelines(PDF)
CL_2022-11.pdf	2022-04-08	ACTION REQUIRED Changes to the Hospital Customer Feedback Process Customer Letter 2022-11 (PDF)
CL_2022-10.pdf	2022-03-21	INFORMATION ONLY 2021 Recombinant Request for Proposals - Zonovate® and Esperoct® Availability & Updates to the Request for Patient Designated Plasma Protein & Related Products Form Customer Letter 2022-10 (PDF) \| Esperoct Welcome Letter (PDF) \| Zonovate Welcome Letter (PDF) \| Zonovate Product Profile (PDF) \| Esperoct Product Profile (PDF) \| F801219 Sample (PDF)
CL_2022-09.pdf	2022-03-18	INFORMATION ONLY Discontinuation of Apheresis Fresh Frozen Plasma 500mL Customer Letter 2022-09 (PDF)
CL_2022-08.pdf	2022-03-14	INFORMATION ONLY J82 Biodegradable Insulator Switchover Customer Letter 2022-08 (PDF)
CL_2022-07.pdf	2022-02-10	INFORMATION ONLY Recommendations for Recipient Notification for Blood Component Recalls Related to COVID-19 Customer Letter 2022-07 (PDF) \| National Recipient Advisory Committee Recommendation (PDF)
CL_2022-06.pdf	2022-02-09	INFORMATION ONLY FAQ for the Request for Proposals (RFP) for Recombinant Plasma Protein and Related Products (PPRP) Customer Letter 2022-06 (PDF) \| 2021 Recombinant RFP FAQ: Process, Results, and Product Availability (PDF)
CL_2022-05.pdf	2022-02-02	INFORMATION ONLY Introduction of Cuvitru® 10g/50mL Customer Letter 2022-05 (PDF) \| Takeda - Introducing a new format of CUVITRU® 10 g/50ml in Canada (PDF)
CL_2022-04.pdf	2022-02-01	INFORMATION ONLY Implementation Update: Introduction of Psoralen Treated Pooled Platelets in Ottawa (to be distributed to hospitals NOT served by Ottawa Site) Customer Letter 2022-04 (PDF)
CL_2022-03.pdf	2022-01-31	INFORMATION ONLY Health Canada approved - Anticoagulant labelling changes for Apheresis products Customer Letter 2022-03 (PDF)
CL_2022-02.pdf	2022-01-25	INFORMATION ONLY Cutaquig® Shelf Life Extension Customer Letter 2022-02 (PDF) \| Cutaquig Extended Shelf Life - Customer Letter (PDF)
CL_2022-01.pdf	2022-01-07	INFORMATION ONLY Implementation Update: Introduction of Psoralen Treated Pooled Platelets (to be distributed to hospitals served by Ottawa Site ONLY) Customer Letter 2022-01 (PDF)